Ticker
Reporting Basis
Period
From
To
Form Type
Report Format
Update Type


MERIDIAN BIOSCI   FYE=9 (September)

Annual - Income Statement - Company Specific

Fiscal period2021202020192018201720162015201420132012
Period End Date9/30/20219/30/20209/30/20199/30/20189/30/20179/30/20169/30/20159/30/20149/30/20139/30/2012
Sales317.90253.67201.01213.57200.77196.08194.83188.83188.69172.71
Total Revenues317.90253.67201.01213.57200.77196.08194.83188.83188.69172.71
Cost of sales116.7597.4282.2982.5476.4868.8772.9571.5967.6463.66
Cost of sales: Sale of product--------------------
Cost of sales: Inventory impairment--------------------
Cost of sales - Plant Consolidation--------------------
Gross Profit201.15156.25118.73131.03124.29127.21121.88117.24121.04109.05
Goodwill impairment charge--------6.63----------
Research and development23.9123.7317.7616.6116.0414.1912.6112.5510.7910.28
Acquired in-process research and development--------------------
General and Administrative49.5444.3534.0435.7631.1029.4327.6227.3930.5226.37
Sales and marketing26.7826.4928.0034.0332.3930.0625.6024.9122.4222.09
Sales and marketing leadership reorganization--------------------
Merger integration costs--------------------
European restructuring costs----------0.68--------
Costs of abandoned acquisition--------------------
Restructuring Costs--0.692.848.710.13----------
Bioline Group transaction costs--------------------
Product recall costs(5.60)------------------
Costs and asset impairment charges related to FDA matters--------------------
Litigation costs------(4.35)(0.63)----------
Acquisition-related costs(0.39)(3.89)(1.81)----(1.48)--------
Plant consolidation costs------------------(1.01)
Change in fair value of contingent consideration obligation0.916.29----------------
Selected legal costs(2.80)(2.08)(1.58)--------------
Total Operating Expenses108.1194.9286.0399.4586.9175.8365.8264.8563.7359.75
Operating Income (loss)93.0361.3232.7031.5837.3851.3856.0652.3957.3149.30
Interest expense1.882.631.951.521.640.90--------
Interest income--0.140.680.420.170.070.020.030.040.04
Other(1.71)0.460.12(0.10)0.520.10(1.02)(0.31)0.000.38
RADx grant income1.00------------------
Earnings before income taxes90.4559.2931.5630.3836.4350.6455.0652.1157.3649.72
Current : State and local1.161.170.831.071.902.422.241.762.011.52
Income tax (benefit) provision19.0413.117.186.5314.8718.4219.5217.3719.3316.35
Foreign------0.400.800.950.890.280.611.02
Federal: Current provision4.431.175.006.0311.26--16.1515.02----
Federal: Fixed asset basis differences and depreciation------0.41(0.18)(0.05)0.050.110.120.00
Federal: Intangible asset basis differences and amortization------(4.05)(1.16)(0.74)(0.42)(0.21)(0.34)(0.35)
Federal: Currently non-deductible expenses and reserves------1.210.88(0.69)0.220.05(0.43)(0.40)
Federal: Stock based compensation------1.38(0.64)0.130.130.06(0.28)(0.60)
Federal: Other, net------(0.15)0.100.180.020.070.040.07
Federal: Currency translation16.3110.191.92--------------
Federal: Net operating loss carryforwards------0.061.83----------
Federal: Abandoned acquisition costs--------------------
Federal: Tax contingency reserve adjustment--------------------
Federal: Tax credit carryforwards------0.180.070.040.250.23(0.72)--
Provision (benefit) for income taxes -Federal -Deferred(2.60)0.74(0.48)--------------
Provision(benefit) for income taxes -Foreign -Deferred(0.26)(0.17)(0.10)--------------
Net Income (loss) Available to Common Shareholders71.4146.1924.3823.8521.5632.2335.5434.7438.0333.37
Net Earnings Per Share (Basic)1.651.080.570.560.510.770.850.840.920.81
Net Earnings Per Share (Diluted)1.621.070.570.560.510.760.850.830.910.80
Weighted Average Shares Outstanding (Basic)43.2642.8642.5742.3342.1942.0141.6641.4641.2341.08
Weighted Average Shares Outstanding (Diluted)44.0143.1742.9042.7542.5742.3942.0141.9141.9041.61